AlzeCure receives approval to start clinical Phase I trial with ACD856 in Alzheimer's disease
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to initiate a clinical Phase I study with the drug candidate ACD856.The Phase I study is AlzeCure's second clinical study with ACD856, the lead drug candidate within the company’s NeuroRestore platform, which is developed as a symptom-relieving treatment for disease states